Framing anticoagulation control according to clinical practice for patients with atrial fibrillation in Spain: a multidisciplinary vision trough AMFA Project.

IF 2.8 3区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS
Frontiers in Cardiovascular Medicine Pub Date : 2025-03-05 eCollection Date: 2025-01-01 DOI:10.3389/fcvm.2025.1426072
Juan Cosín-Sales, Jose Polo-García, Olga Gavín Sebastián, Marta Rubio Cabezas, María Lloret Avellá
{"title":"Framing anticoagulation control according to clinical practice for patients with atrial fibrillation in Spain: a multidisciplinary vision trough AMFA Project.","authors":"Juan Cosín-Sales, Jose Polo-García, Olga Gavín Sebastián, Marta Rubio Cabezas, María Lloret Avellá","doi":"10.3389/fcvm.2025.1426072","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction and objectives: </strong>The use of vitamin K antagonists (VKA) in patients with atrial fibrillation (AF) in Spain remains high, even though the available data on anticoagulation control (TRT, time in therapeutic range) shows suboptimal results. The objective of the AMFA project, an atlas of the management of anticoagulation in patients with AF, was to describe oral anticoagulation management in Spanish´ patients.</p><p><strong>Materials and methods: </strong>The AMFA Project is a descriptive, multicenter study. It included information from 60 healthcare areas from each of the 17 Spanish regions. Consensus methodologies were used to analyze qualitative information obtained from the physicians' experience and perception and quantitative data collected through a specialized study questionnaire. In this questionnaire, experts were asked to include data of the last 10 consecutive patients attended with AF on anticoagulation treatment.</p><p><strong>Results: </strong>Records from 1,580 patients were obtained from 176 experts. Of them, 34.7% were cardiologists, 32.9% general practitioners (GPs), and 32.4% hematologists. The utilization rates of Direct Oral Anticoagulants (DOACs) and VKAs in clinical practice was 55.8% and 43.3%, respectively, which was not correlated with experts' perception. Clinical practice data revealed that 30.3% of the patients included did not have international normalized ratio (INR) or TTR data available, while only 3.8% of the experts reported that INR/TTR information was not available according to their perception. Considering only patients who had INR and TTR available, clinical practice showed that 59.0% of the patients had their coagulation in range, while the remaining 41.0% were uncontrolled. This result matches with the general perception reported by the experts, 62.6% of patients in range. Additionally, up to 22.2% of patients received DOAC treatment at suboptimal doses.</p><p><strong>Conclusions: </strong>These data highlight the suboptimal control of the INR of patients, as well as the difficulties in DOACs access in Spain. The study uncovers the need to implement actions to improve INR control, facilitate access to DOACs treatment, and standardize AF patients' management. Establishing protocols that facilitate intervention may optimize the management of the patients with AF.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"12 ","pages":"1426072"},"PeriodicalIF":2.8000,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11919873/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Cardiovascular Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fcvm.2025.1426072","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction and objectives: The use of vitamin K antagonists (VKA) in patients with atrial fibrillation (AF) in Spain remains high, even though the available data on anticoagulation control (TRT, time in therapeutic range) shows suboptimal results. The objective of the AMFA project, an atlas of the management of anticoagulation in patients with AF, was to describe oral anticoagulation management in Spanish´ patients.

Materials and methods: The AMFA Project is a descriptive, multicenter study. It included information from 60 healthcare areas from each of the 17 Spanish regions. Consensus methodologies were used to analyze qualitative information obtained from the physicians' experience and perception and quantitative data collected through a specialized study questionnaire. In this questionnaire, experts were asked to include data of the last 10 consecutive patients attended with AF on anticoagulation treatment.

Results: Records from 1,580 patients were obtained from 176 experts. Of them, 34.7% were cardiologists, 32.9% general practitioners (GPs), and 32.4% hematologists. The utilization rates of Direct Oral Anticoagulants (DOACs) and VKAs in clinical practice was 55.8% and 43.3%, respectively, which was not correlated with experts' perception. Clinical practice data revealed that 30.3% of the patients included did not have international normalized ratio (INR) or TTR data available, while only 3.8% of the experts reported that INR/TTR information was not available according to their perception. Considering only patients who had INR and TTR available, clinical practice showed that 59.0% of the patients had their coagulation in range, while the remaining 41.0% were uncontrolled. This result matches with the general perception reported by the experts, 62.6% of patients in range. Additionally, up to 22.2% of patients received DOAC treatment at suboptimal doses.

Conclusions: These data highlight the suboptimal control of the INR of patients, as well as the difficulties in DOACs access in Spain. The study uncovers the need to implement actions to improve INR control, facilitate access to DOACs treatment, and standardize AF patients' management. Establishing protocols that facilitate intervention may optimize the management of the patients with AF.

根据西班牙房颤患者的临床实践框架抗凝控制:通过AMFA项目的多学科愿景。
简介和目的:在西班牙,维生素K拮抗剂(VKA)在房颤(AF)患者中的使用率仍然很高,尽管抗凝控制(TRT,治疗范围内时间)的现有数据显示效果不理想。AMFA项目是房颤患者抗凝治疗的地图集,其目的是描述西班牙患者的口服抗凝治疗。材料和方法:AMFA项目是一项描述性、多中心研究。它包括来自西班牙17个大区各60个保健领域的信息。共识方法用于分析从医生的经验和感知中获得的定性信息以及通过专门研究问卷收集的定量数据。在这份问卷中,专家被要求包括最近10个连续接受抗凝治疗的房颤患者的数据。结果:从176名专家处获得1580例患者病历。其中34.7%为心脏科医生,32.9%为全科医生,32.4%为血液科医生。直接口服抗凝剂(DOACs)和vka在临床中的使用率分别为55.8%和43.3%,与专家的认知无关。临床实践数据显示,30.3%的患者没有国际标准化比率(INR)或TTR数据,而只有3.8%的专家报告根据他们的感知没有INR/TTR信息。仅考虑可获得INR和TTR的患者,临床实践表明,59.0%的患者凝血在范围内,其余41.0%不受控制。这一结果与专家报告的普遍看法相吻合,62.6%的患者在范围内。此外,高达22.2%的患者接受了次优剂量的DOAC治疗。结论:这些数据突出了西班牙患者INR控制的次优,以及DOACs获得的困难。该研究揭示了采取措施改善INR控制、促进获得DOACs治疗和规范房颤患者管理的必要性。建立有利于干预的方案可以优化对房颤患者的管理。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Frontiers in Cardiovascular Medicine
Frontiers in Cardiovascular Medicine Medicine-Cardiology and Cardiovascular Medicine
CiteScore
3.80
自引率
11.10%
发文量
3529
审稿时长
14 weeks
期刊介绍: Frontiers? Which frontiers? Where exactly are the frontiers of cardiovascular medicine? And who should be defining these frontiers? At Frontiers in Cardiovascular Medicine we believe it is worth being curious to foresee and explore beyond the current frontiers. In other words, we would like, through the articles published by our community journal Frontiers in Cardiovascular Medicine, to anticipate the future of cardiovascular medicine, and thus better prevent cardiovascular disorders and improve therapeutic options and outcomes of our patients.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信